Arrivent Biopharma Inc (AVBP)

$22.64 -0.03 (-0.15%)
Market Cap 928.41M
Revenue (ttm) 0.00
Net Income (ttm) -80.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,337,700
Avg Vol 421,034
Day's Range N/A - N/A
Shares Out 41.28M
Stochastic %K 21%
Beta 1.03
Analysts Strong Sell
Price Target $40.75

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology
Sector: Healthcare
Phone: 628 277 4836
Address:
18 Campus Boulevard, Suite 100, Newtown Square, United States
judgeyoung2
judgeyoung2 Feb. 3 at 9:06 PM
$AVBP data might be coming tomorrow. elevated volume for seemingly no reason.
1 · Reply
JFais
JFais Jan. 23 at 1:09 PM
This week in Chat: -A number of interesting setups shared in our Non-Biotech channel, including Crypto & Tokenization side of things -Good back and forth on $CRVS, quite a few people owned into the data (vs selling early like I did 🤦‍♂️). Implications for evolving atopic dermatitis landscape & increased market penetration estimates (IF data holds up in higher N of patients). Not to mention impact on confidence level into pivotal PTCL readout and potential to soon move forward in expansion indications like asthma & HS). IP to 2042= long-lived per CEO but others think it's only to 2037 (plenty of time to develop soquelitinib in other indications as well as move next-gen ITK inhibitors forward) Also, noteworthy discussions in $GLUE, $CELC, $VIR, $AVBP among others
0 · Reply
judgeyoung2
judgeyoung2 Jan. 22 at 5:57 PM
$AVBP it reminds me of PRAX bc no one is watching it. keep in mind PRAX was randomly up 13% also the day before data dropped.
1 · Reply
AlphaAlpaca
AlphaAlpaca Jan. 22 at 3:52 PM
$AVBP slowly but surely 💪 The Alpaca gonna lock in some profits and let the rest ride
0 · Reply
judgeyoung2
judgeyoung2 Jan. 22 at 1:27 AM
$AVBP strangled for data readout
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 7:42 PM
$AVBP RSI: 54.31, MACD: -0.0910 Vol: 1.12, MA20: 21.08, MA50: 21.53 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
judgeyoung2
judgeyoung2 Jan. 20 at 4:09 PM
$AVBP @cubie any interesting flow here ?
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Jan. 19 at 4:25 AM
$AVBP what's going on here? Exon 20 data readout upcoming. Pfs is the primary end point, derisked via Chinese data? Why no love? Anyone got an investor conference link?
1 · Reply
Quantumup
Quantumup Jan. 16 at 12:19 PM
BTIG (a/o Dec. 10),🏁 $AVBP at a Buy rating and a $45 PT. $ORIC $BDTX Cantor (a/o Dec 22),🏁 $AVBP at an Overweight rating. Oppenheimer (a/o Jan. 6), reiterated $AVBP at an Outperform rating and a $44 PT Here's what the Analysts had to say:
0 · Reply
AlphaAlpaca
AlphaAlpaca Jan. 13 at 8:54 PM
$AVBP running nicely as expected 💪
0 · Reply
Latest News on AVBP
ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy

Jan 4, 2026, 3:26 AM EST - 4 weeks ago

ArriVent BioPharma: Its Leading Asset Furmonertinib Supports A Cautious Buy

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts

Dec 25, 2025, 8:30 AM EST - 5 weeks ago

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Dec 22, 2025, 8:00 AM EST - 6 weeks ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 3 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 22, 2025, 4:05 PM EDT - 4 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Sep 9, 2025, 8:00 AM EDT - 5 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 8:00 AM EDT - 6 months ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 21, 2025, 8:00 AM EDT - 7 months ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jul 2, 2025, 8:22 AM EDT - 7 months ago

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BV CNC

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 11:15 PM EDT - 7 months ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 7 months ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 23, 2025, 7:00 AM EDT - 8 months ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Jun 20, 2025, 4:05 PM EDT - 8 months ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

ArriVent BioPharma Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 9 months ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 28, 2025, 8:00 AM EDT - 10 months ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Sep 9, 2024, 12:05 PM EDT - 1 year ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 15, 2024, 7:01 AM EDT - 1 year ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:01 PM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Aug 12, 2024, 8:00 AM EDT - 1 year ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Jun 5, 2024, 7:00 AM EDT - 1 year ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 16, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

ArriVent Appoints Kristine Peterson to its Board of Directors

Apr 22, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints Kristine Peterson to its Board of Directors

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

ArriVent BioPharma Reports Full Year 2023 Financial Results

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

Jan 29, 2024, 6:15 PM EST - 2 years ago

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

judgeyoung2
judgeyoung2 Feb. 3 at 9:06 PM
$AVBP data might be coming tomorrow. elevated volume for seemingly no reason.
1 · Reply
JFais
JFais Jan. 23 at 1:09 PM
This week in Chat: -A number of interesting setups shared in our Non-Biotech channel, including Crypto & Tokenization side of things -Good back and forth on $CRVS, quite a few people owned into the data (vs selling early like I did 🤦‍♂️). Implications for evolving atopic dermatitis landscape & increased market penetration estimates (IF data holds up in higher N of patients). Not to mention impact on confidence level into pivotal PTCL readout and potential to soon move forward in expansion indications like asthma & HS). IP to 2042= long-lived per CEO but others think it's only to 2037 (plenty of time to develop soquelitinib in other indications as well as move next-gen ITK inhibitors forward) Also, noteworthy discussions in $GLUE, $CELC, $VIR, $AVBP among others
0 · Reply
judgeyoung2
judgeyoung2 Jan. 22 at 5:57 PM
$AVBP it reminds me of PRAX bc no one is watching it. keep in mind PRAX was randomly up 13% also the day before data dropped.
1 · Reply
AlphaAlpaca
AlphaAlpaca Jan. 22 at 3:52 PM
$AVBP slowly but surely 💪 The Alpaca gonna lock in some profits and let the rest ride
0 · Reply
judgeyoung2
judgeyoung2 Jan. 22 at 1:27 AM
$AVBP strangled for data readout
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 7:42 PM
$AVBP RSI: 54.31, MACD: -0.0910 Vol: 1.12, MA20: 21.08, MA50: 21.53 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
judgeyoung2
judgeyoung2 Jan. 20 at 4:09 PM
$AVBP @cubie any interesting flow here ?
1 · Reply
Doom_Gloom_AR
Doom_Gloom_AR Jan. 19 at 4:25 AM
$AVBP what's going on here? Exon 20 data readout upcoming. Pfs is the primary end point, derisked via Chinese data? Why no love? Anyone got an investor conference link?
1 · Reply
Quantumup
Quantumup Jan. 16 at 12:19 PM
BTIG (a/o Dec. 10),🏁 $AVBP at a Buy rating and a $45 PT. $ORIC $BDTX Cantor (a/o Dec 22),🏁 $AVBP at an Overweight rating. Oppenheimer (a/o Jan. 6), reiterated $AVBP at an Outperform rating and a $44 PT Here's what the Analysts had to say:
0 · Reply
AlphaAlpaca
AlphaAlpaca Jan. 13 at 8:54 PM
$AVBP running nicely as expected 💪
0 · Reply
AlphaAlpaca
AlphaAlpaca Jan. 12 at 5:09 PM
$AVBP took a small position here. Should see a bit of a run up as we near Phase 3 data read out.
1 · Reply
BillionerOfKing
BillionerOfKing Jan. 1 at 8:15 PM
$AVBP Current Stock Price: $20.13 Contracts to trade: $20 AVBP Jan 16 2026 Call Entry: $0.30 Exit: $0.58 ROI: 93% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
justiceforb_85
justiceforb_85 Dec. 31 at 9:07 PM
$AVBP great time to add.
0 · Reply
ApexPulseNavigator
ApexPulseNavigator Dec. 27 at 7:46 AM
$AVBP Risk tolerance remains selective and tied closely to execution credibility. Forecast reliability has room to improve materially. Credible progress tends to compress risk premiums. Patience is warranted — but must be supported by results.
1 · Reply
JarvisFlow
JarvisFlow Dec. 23 at 12:56 PM
Cantor Fitzgerald updates rating for ArriVent BioPharma ( $AVBP ) to Overweight.
0 · Reply
notreload_ai
notreload_ai Dec. 23 at 10:57 AM
Cantor Fitzgerald initiates coverage on $AVBP with an Overweight rating, highlighting strong Phase 3 potential and significant upside. https://notreload.xyz/cantor-fitzgerald-starts-coverage-on-arrivent-biopharma-with-strong-upside/
0 · Reply
prismmarketview
prismmarketview Dec. 22 at 4:03 PM
ArriVent BioPharma (Nasdaq: $AVBP) has dosed the first patient in its global Phase 3 ALPACCA trial evaluating firmonertinib as a first-line, chemo-free treatment for EGFR PACC mutant NSCLC—an underserved population with limited targeted options. https://prismmarketview.com/arrivent-doses-first-patient-in-pivotal-phase-3-alpacca-trial-for-egfr-pacc-mutant-lung-cancer/
0 · Reply
UgoGreg
UgoGreg Dec. 20 at 6:02 PM
$AVBP https://youtu.be/ygBN8MilTyc
0 · Reply
justiceforb_85
justiceforb_85 Dec. 18 at 4:36 AM
$AVBP looking forward to P3 result for 1L exon 20 NSCLC early next year.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 12:33 PM
BTIG updates rating for ArriVent BioPharma ( $AVBP ) to Buy, target set at 45.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:09 AM
$BDTX over-reaction as I think silevertinib will have a place in 1L non-classical mutations with the exception of PACC where $AVBP will be the leader. Main concern is whether BP will partner with (or buy outright) the company to run a P3 for non-classical NSCLC.
1 · Reply